RCKT
Rocket Pharmaceuticals, Inc. · Healthcare · Biotechnology
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q2 2024
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 80 | -1 | 55.09M | $188.40M | +4 | −5 |
| Q1 2026 | 83 | +2 | 57.14M | $204.44M | +8 | −6 |
| Q4 2025 | 81 | +2 | 51.01M | $179.05M | +2 | — |
| Q3 2025 | 15 | 0 | 38.20M | $124.54M | — | — |
| Q2 2025 | 12 | -1 | 25.35M | $62.12M | +2 | −3 |
| Q1 2025 | 10 | -1 | 24.61M | $164.16M | +1 | −2 |
| Q4 2024 | 11 | 0 | 29.17M | $366.63M | +1 | −1 |
| Q3 2024 | 10 | 0 | 19.68M | $363.43M | +2 | −2 |
| Q2 2024 | 10 | — | 17.23M | $370.95M | — | — |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 9.16M | — | $197.12M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 9.16M | — | $197.12M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 9.16M | — | $197.12M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 9.16M | — | $197.12M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 9.16M | — | $197.12M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 9.16M | — | $197.12M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 9.16M | — | $197.12M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 9.16M | — | $197.12M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | T. Rowe Price ✦ | 3.17M | — | $68.24M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 3.17M | — | $68.24M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 2.82M | — | $60.67M | 0.1% | n/c | 1 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 2.82M | — | $60.67M | 0.1% | n/c | 1 | SEC ↗ |
| 13 | Geode Capital Management ✦ (pasivo) | 1.60M | — | $34.53M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Geode Capital Management ✦ (pasivo) | 1.60M | — | $34.53M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Adage Capital Partners ✦ | 200.00K | — | $4.31M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Millennium Management ✦ | 105.33K | — | $2.27M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Renaissance Technologies ✦ | 99.57K | — | $2.14M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Norges Bank ✦ (pasivo) | 34.75K | — | $748,211 | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Two Sigma Investments ✦ | 23.09K | — | $497,149 | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Marshall Wace ✦ | 19.58K | — | $421,622 | 0.0% | n/c | 1 | SEC ↗ |
«Su ponderación» = la participación de la posición en el valor de renta variable 13F declarado por ese gestor — la medida de convicción. ✦ = gestor seleccionado.
Nuevos compradores
| Sin nuevos compradores rastreados este trimestre. |
Posición cerrada
| Sin salidas rastreadas este trimestre. |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 195 tenedores, 96.37M acciones, $341.40M declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué otros valores suelen tener también los tenedores rastreados de este activo — recuentos de cotenencia, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Officer · 2.29K acc. · $7,753
Officer · 631 acc. · $2,133
Officer · 4.70K acc. · $16,449
Officer · 36.66K acc. · $128,266
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología